AZD4547

For research use only. Not for use in humans.

目录号:S2801

AZD4547 Chemical Structure

CAS No. 1035270-39-3

AZD4547是一种新型选择性的FGFR抑制剂,靶向作用于FGFR1/2/3,在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM,对FGFR4, VEGFR2(KDR)具有微弱的作用活性,对IGFR, CDK2和p38几乎没有作用活性。Phase 2/3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1801.43 现货
RMB 901.31 现货
RMB 1395.39 现货
RMB 4661.52 现货
RMB 7125.05 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的AZD4547发表文献78篇:

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述 AZD4547是一种新型选择性的FGFR抑制剂,靶向作用于FGFR1/2/3,在无细胞试验中IC50为0.2 nM/2.5 nM/1.8 nM,对FGFR4, VEGFR2(KDR)具有微弱的作用活性,对IGFR, CDK2和p38几乎没有作用活性。Phase 2/3。
特性 AZD4547高选择性作用于 FGFR1-3,比作用于FGFR4选择性高。AZD4547有效作用于野生型和突变型FGFR酪氨酸激酶活性。
靶点
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
KDR [1]
(Cell-free assay)
0.2 nM 1.8 nM 2.5 nM 24 nM
体外研究

与 FGFR1-3相比, AZD4547作用于FGFR4,活性微弱,IC50为165 nM。AZD4547 只抑制重组 VEGFR2 (KDR) 激酶活性, IC50为 24 nM,在体外选择性作用于一组多种代表性的人类激酶。0.1 μM AZD4547 作用于一系列重组激酶,包括 ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2,和 PI3K,没有作用活性。相应地,在细胞磷酸化实验中,可观察到AZD4547 作用于FGFR1-3的选择性比作用于 FGFR4, IGFR, 和 KDR高。AZD4547在体外,只有作用于表达去调控FGFRs 如KG1a, Sum52-PE,和KMS11的肿瘤细胞,具有有效抗增殖活性,IC50 为18-281 nM,而对MCF7 及100 种以上其他肿瘤细胞无活性。AZD4547 处理人类肿瘤细胞,有效抑制FGFR 和 MAPK 磷酸化,这种作用存在剂量依赖性。AZD4547 也有效抑制FRS2 和 PLCγ磷酸化,及下游FGFR信号。另外, AZD4547作用于乳腺细胞系,MCF7和Sum52-PE 而不是KG1a和 KMS11细胞,影响AKT磷酸化。AZD4547处理Sum52-PE 和 KMS11细胞,显著诱导凋亡,作用于KG1a细胞,显著提高细胞周期在G1期停滞而不是凋亡, 而作用于MCF7细胞,对细胞周期分布和凋亡都没有作用效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SNU449 M3HW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm3cG44OiCq NHjHbWVKSzVyPUCuNFgzKM7:TR?= MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlAoRjJ4M{WxN|IxRC:jPh?=
SK-HEP-1 NHHpbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHDfIY4OiCq M4X3UmlEPTB;MD6wPFQh|ryP M1TaPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|IxLz5{NkO1NVMzODxxYU6=
SNU475 NYHocppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUO3NkBp NGTydphKSzVyPUWuOEDPxE1? NF6wd3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO1NVMzOCd-Mk[zOVE{OjB:L3G+
Hep3B M2TndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH3O|IhcA>? M4\jcWlEPTB;Nj60N{DPxE1? M1izT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|IxLz5{NkO1NVMzODxxYU6=
PLC/PRF5 NV[2[IJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDsO|IhcA>? MXvJR|UxRTZwNUWg{txO M4ixcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|IxLz5{NkO1NVMzODxxYU6=
Hur7 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jCclczKGh? NVn6VHV[UUN3ME23MlI2KM7:TR?= MnfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlAoRjJ4M{WxN|IxRC:jPh?=
HepG2 NYPkSIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLYSnI6PzJiaB?= MXrJR|UxRThwN{Og{txO MoLDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUGzNlAoRjJ4M{WxN|IxRC:jPh?=
SNU449 MlSzR4xwdm:pZX7pZ{Bie3OjeR?= MVOxJOK2VQ>? NH3GUHczPCCq NUPZZWds\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ|NUGzNlA9N2F-
SK-HEP-1 NVTYS5BqS2yxbn;n[Y5q[yCjc4PhfS=> Mo[2NUDDvU1? MWSyOEBp MnP6[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgQ>? M4n6d|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{WxN|IxLz5{NkO1NVMzODxxYU6=
SNU449 M2e1PWZ2dmO2aX;uJGF{e2G7 NWnST4lQOC1{IN88US=> MofLOFghcA>? MWTjZZV{\XNiYTDk[YNz\WG|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=> NYL0ephPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVE{OjBpPkK2N|UyOzJyPD;hQi=>
SK-HEP-1 MVHGeY5kfGmxbjDBd5NigQ>? M4fVVFAuOiEQvF2= M1HERlQ5KGh? MVnjZZV{\XNiYTDk[YNz\WG|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3MUOyNEc,OjZ|NUGzNlA9N2F-
BaF3 FLT3-TEL NXjRS45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXISmlqT0l3ME20MlYhyrFiMD61O|ch|ryP NUDNTGhwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
BaF3 RET-TEL NGDOb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDmSmNIUTVyPUCuN|khyrFiMD6wOFgh|ryP MmruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
BaF3 Parental M4e1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z1dmdKPTExubWxNEDPxE1? MmPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
MOLM14 FLT3/ITD NIO0SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\rZpUxT0l3ME2wMlQ5PCEEsTCwMlE2PyEQvF2= Mm[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
MV4-11 FLT3/ITD MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DLcWdKPTB;MD60OVkhyrFiMD6wOFYh|ryP MmrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
TT RET C634W MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm5VZNNT0l3ME2yMlkhyrFiMD65NFQh|ryP MlrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
AN3-CA FGFR2 N550K, K310R MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSyS2k2OD1yLkCzNUDDuSByLkCyN{DPxE1? Mn[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OUS3OFEoRjJ4Mkm0O|QyRC:jPh?=
MFE296 FGFR2 N550K NIXJUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInYU4dIUTVyPUCuO|MxKMLzIECuNFU4KM7:TR?= NUPXT21yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
MFE280 FGFR2 S252W NVLmUVQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXl[FRJT0l3ME2wMlIyQCEEsTCwMlA4OyEQvF2= NVWxT|RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
Ishikawa FGFF2 over exp. M3;Ddmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tS2k2OD12LkWgxtEhOS53MTFOwG0> NYrKW|BDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPVQ4PDFpPkK2Nlk1PzRzPD;hQi=>
HEC1A Normal FGFR2 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\xcW1IUTVy78olNVAh|ryP NH3uTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK5OFc1OSd-Mk[yPVQ4PDF:L3G+
A549 NWDDN|F4S2WubDD2bYFjcWyrdImgRZN{[Xl? MU[wMlEwOSEQvF2= NEXQeHE1QCCq MULlcohidmOnczDFdoxwfGmwaXKgbY5lfWOnZDD2bYFjcWyrdImgcI9{ew>? NYD0N|V[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVMxOjBpPkK2NFU{ODJyPD;hQi=>
SGC-7901 M4jmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjYNUBvVS1zMDFOwG0> MlO1O|IhcA>? NHzQ[25KSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NX;pV4dCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|Y6OTVpPkK1OVc3QTF3PD;hQi=>
HGC-27 M3TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV34cIdwOSCwTT2xNEDPxE1? NEXsXJI4OiCq NEPn[o9KSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NH7Ffmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW3OlkyPSd-MkW1O|Y6OTV:L3G+
MKN-28 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSxJI5ONTFyIN88US=> MXG3NkBp NIGzbXlKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYGzdJBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|Y6OTVpPkK1OVc3QTF3PD;hQi=>
NCI-N87 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmxJI5ONTFyIN88US=> Mn;uO|IhcA>? MWLJR|UxKG:oIEWtNVAh|ryPLDDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NVnNbmNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|Y6OTVpPkK1OVc3QTF3PD;hQi=>
KATOIII M3vnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XXXlEhdk1vMUCg{txO NGqwfmI4OiCq MVHJR|UxKG:oIEGwMVExOCCwTTygbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV5NkmxOUc,OjV3N{[5NVU9N2F-
SNU-16 NF\wfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrHNGoyKG6PLUGwJO69VQ>? M1nyRlczKGh? Ml3UTWM2OCCxZjCxNE0yODBibl2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NX6yNHB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1O|Y6OTVpPkK1OVc3QTF3PD;hQi=>
4T1 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i0PGlEPTB;MD62OOKyOC5zMTFOwG0> M3HISFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
MDA-MB-468 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojrTWM2OD12LkpCtVAvQDVizszN MkfxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NEK4PVMoRjJ2NkSyPFk{RC:jPh?=
HCT116 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH3eGFKSzVyPUG1MlnDuTFwOEKg{txO NVW3UlQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFI5QTNpPkK0OlQzQDl|PD;hQi=>
SW620 NF\BOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr3R29sUUN3MP-8olIxKM7:TR?= M1LuTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
MDA-MB-231 M4DHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjicVhKSzVy78{eNlAh|ryP M2izOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
CT26 M{DMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLWXpJKSzVy78{eNlAh|ryP MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2Mki5N{c,OjR4NEK4PVM9N2F-
SW480 M4rld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3HTWM2OO,:nkKwJO69VQ>? M3[z[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkSyPFk{Lz5{NE[0Nlg6OzxxYU6=
4T1 MnvrRZBweHSxc3nzJGF{e2G7 NE\IfW4yNjJ3LUKwJO69VQ>? NUHPTFlkOjRiaB?= MnOzbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NWjmPIZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OFI5QTNpPkK0OlQzQDl|PD;hQi=>
KG1a NXnhfXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjqWmhKSzVyPUCuNFE5KM7:TR?= NU\ReY9TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlk6OjhpPkKyN|Y6QTJ6PD;hQi=>
Sum52-PE NHu3enhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMESxJO69VQ>? MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN4OUmyPEc,OjJ|Nkm5Nlg9N2F-
KMS11 NEPvTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[weGlEPTB;MD6yPFEh|ryP MkXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ|Nkm5NlgoRjJ{M{[5PVI5RC:jPh?=
MCF7 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTPTWM2OD5|MDFOwG0> NHGyd2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO2PVkzQCd-MkKzOlk6Ojh:L3G+
KG1 NYfVfFU2TnWwY4Tpc44h[XO|YYm= NH3lcmc4OiCqcoO= MYPJcohq[mm2aX;uJI9nKE[JRmKxJIlvKGi3bXHuJGtIOSClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNFAxOiEQvF2u NV32Rm9qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVc1OjdpPkK3NVE4PDJ5PD;hQi=>
RT112 NIjod21HfW6ldHnvckBie3OjeR?= NEm3cZc4OiCqcoO= MULJcohq[mm2aX;uJI9nKE[JRmKzJIlvKGi3bXHuJHJVOTF{IHPlcIx{KGG|c3Xzd4VlKGG|IIP1dJBz\XO|aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhW1KEL1PDT{05KGG|c3H5MEBKSzVyIE2gNE4xODB4IN88UU4> NYPPe|BiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVc1OjdpPkK3NVE4PDJ5PD;hQi=>
KG1 MY\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M4T2UFczKGi{cx?= NUHWd4JjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLS|Eh[2WubIOg[ZhxemW|c3nu[{BHT0[UMTDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjByMUmg{txONg>? NX7vRm02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O|U6OzdpPkK5O|c2QTN5PD;hQi=>
KG1 M1zEcmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NYDBenNQPzJiaILz NGjXVoxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvHNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLMVgh[XO|YYmsJGlEPTBiPTCwMlAxOzNizszNMi=> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ6N{KwOEc,Ojh4OEeyNFQ9N2F-
SNU16 MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYPhW2EzPzJiaILz MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQVUG2JINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFQ1utPEBie3OjeTygTWM2OCB;IECuNFA{PCEQvF2u MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4OEeyNFQoRjJ6Nki3NlA1RC:jPh?=
SNU16 MVjGeY5kfGmxbjDhd5NigQ>? M2P5NFczKGi{cx?= NIrOSZRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGZITlJ{IHnuJIh2dWGwIGPOWVE3KGOnbHzzJIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR|UxKD1iMD6wNFM3KM7:TT6= MkH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUe0NlcoRjJ5MUG3OFI4RC:jPh?=
SNU16 NFywXVZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NHn0NYw4OiCqcoO= Ml3TRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVTmWxOkBk\WyuczDlfJBz\XO|aX7nJGZITlJ{IHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvODB4MjFOwG0v MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N|c9N2F-
KG1 M4HtT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 M1HMXlczKGi{cx?= M{L3XGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmdHWjFvdILhcpNtd2OjdHXkJIh2dWGwIFvHNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLPE9OXFRiYYPzZZktKEmFNUCgQUAxNjByNkSg{txONg>? Ml7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NEi1N|coRjJ5M{S4OVM4RC:jPh?=
SNU16 M4PGVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MUS3NkBpenN? MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF\HSnIzNWGvcHzp[olm\CCqdX3hckBUVlVzNjDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONOD;NWHQh[XO|YYmsJGlEPTBiPTCwMlAyOzRizszNMi=> MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NEi1N|coRjJ5M{S4OVM4RC:jPh?=
KATO III MUHGeY5kfGmxbjDhd5NigQ>? M4r2NVczKGi{cx?= MYLJcohq[mm2aX;uJI9nKE[JRmKyJIlvKGi3bXHuJGtCXE9iSVnJJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSClZXzsJINwfW62aX7nJItqfC16IHHzd4F6NCCLQ{WwJF0hOC5yMUSxJO69VS5? NHzXbWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
KG1 M{jVTGZ2dmO2aX;uJIF{e2G7 NGDnfJE4OiCqcoO= MkK3TY5pcWKrdHnvckBw\iCIR1\SNW9ROiCodYPl[EBHT0[UMTDpckBpfW2jbjDLS|Eh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkCxOlEh|ryPLh?= NFrrUXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
KATO III NHTmc3ZHfW6ldHnvckBie3OjeR?= MoryO|IhcHK| NWrqWYdbUW6qaXLpeIlwdiCxZjDGS2ZTOiCrbjDoeY1idiCNQWTPJGlKUSClZXzsd{Bie3Onc4Pl[EBieyC|dYDwdoV{e2mxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO|IhcHK|IHL5JHNTSi:FQ1utPEBie3OjeTygTWM2OCB;IECuNFIxOiEQvF2u MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzN{SyO{c,OjdzMUe0Nlc9N2F-
SNU16 MVHGeY5kfGmxbjDhd5NigQ>? MoezO|IhcHK| NYTnc4ZDUW6qaXLpeIlwdiCxZjDGS2ZTOiCrbjDoeY1idiCVTmWxOkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK1OEDPxE1w MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNE[5Nkc,Ojh5MUS2PVI9N2F-
UM-UC-14 NXHheWlqSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NFzFOpA4OiCqcoO= NEnnXmVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGXNMXVENTF2IHPlcIx{KGW6cILld5NqdmdiRlfGVlMh[W[2ZYKgO|IhcHK|LDDJR|UxKD1iMD6wNlY6KM7:TT6= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N|c9N2F-
RT112 MYjGeY5kfGmxbjDhd5NigQ>? M3LT[lczKGi{cx?= NVzje5Z6UW6qaXLpeIlwdiCxZjDGS2ZTOyCrbjDoeY1idiCUVEGxNkBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK3JO69VS5? NHXoWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEexOFY6Oid-Mki3NVQ3QTJ:L3G+
UM-UC-14 MlvOSpVv[3Srb36gZZN{[Xl? MXe3NkBpenN? NH;XdY5KdmirYnn0bY9vKG:oIF\HSnI{KG23dHHueEBqdiCqdX3hckBWVS2XQz2xOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliY3XscEBkd3WwdHnu[{BscXRvODDhd5NigSxiSVO1NEA:KDBwMEK3NUDPxE1w MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNE[5Nkc,Ojh5MUS2PVI9N2F-
RT112 Ml[zRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWfmV4pyPzJiaILz MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKWMUGyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkCyPVIh|ryPLh?= MnG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3OUm3OFIoRjJ5NUm5O|QzRC:jPh?=
H1581 NGKwXXJHfW6ldHnvckBie3OjeR?= NULlUYo3PzJiaILz NX\pS49TUW6qaXLpeIlwdiCxZjDGS2ZTOSCrbjDoeY1idiCKMUW4NUBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRk9ES0tvODDhd5NigSxiSVO1NEA:KDBwMEOyPUDPxE1w NUDDSHMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVc1OjdpPkK3NVE4PDJ5PD;hQi=>
NCI-H1581 NF\NfldCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3vOVFczKGi{cx?= Ml;vRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFE2QDFiY3XscJMh\XiycnXzd4lv\yCIR1\SNUBi\nSncjC3NkBpenNuIFnDOVAhRSByLkC0JO69VS5? Ml70QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{W5N|coRjJ7N{e1PVM4RC:jPh?=
B16F10 M3i2e2N6fG:2b4jpZ4l1gSCjc4PhfS=> M1zyR|czKGi{cx?= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODVzIN88UU4> MmrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{[5PVMoRjJ3N{O2PVk{RC:jPh?=
A549 M1jue2N6fG:2b4jpZ4l1gSCjc4PhfS=> M2S4eFczKGi{cx?= NWS0dm5QS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yNkKg{txONg>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd|Nkm5N{c,OjV5M{[5PVM9N2F-
NCI-H1581 M4nJdGZ2dmO2aX;uJIF{e2G7 NF3tT5o4OiCqcoO= MkjjTY5pcWKrdHnvckBw\iCIR1\SNUBqdiCqdX3hckBPS0lvSEG1PFEh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IHPlcIwh[2:3boTpcochc2m2LUigZZN{[XluIFnDOVAhRSByLkC2NlYh|ryPLh?= M3i5[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{G0OlkzLz5{OEexOFY6OjxxYU6=
RT112 NYHHZZJJSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NXWxWHRYPzJiaILz NFmwdppCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLUNVEzKGOnbHzzJIV5eHKnc4PpcochTkeIUkOgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5yOEO4JO69VS5? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N|c9N2F-
RT112 NYDEfZFOSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MnzkO|IhcHK| NVHKblc3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBHT0[UMz3hcZBtcW[rZXSgbJVu[W5iUmSxNVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT|gwVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOEi0JO69VS5? MmrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NEi1N|coRjJ5M{S4OVM4RC:jPh?=
NCI-H1581 NVvkOplISW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NF7kTG84OiCqcoO= NHTIVYNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGZITlJzLXHtdIxq\mmnZDDoeY1idiCQQ1mtTFE2QDFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNEUzhxTWTUJIF{e2G7LDDJR|UxKD1iMD6wPVIyKM7:TT6= MnO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd|NEi1N|coRjJ5M{S4OVM4RC:jPh?=
HeLa 229 MWfDfZRwfG:6aXPpeJkh[XO|YYm= NUXaSYk4PzJiaILz Ml:0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SB{MkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUSg{txONg>? M1jqXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{O2PVk{Lz5{NUezOlk6OzxxYU6=
BAF3 NXPTV2M3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3z6cVczKGi{cx?= M2m0VWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDlfJBz\XO|aX7nJHZGT0[UMjDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ{MjFOwG0v MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUmzO{c,Ojl5N{W5N|c9N2F-
SGC7901 M4rrWmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3LF[VczKGi{cx?= M4HCXGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1fDO|kxOSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNk45KM7:TT6= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh{OUWxPUc,Ojd6Mkm1NVk9N2F-
MGC803 MlP4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M{HWXVczKGi{cx?= NXO5TYZ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNS2M5ODNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFYvOiEQvF2u NVO2WGlrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4Nlk2OTlpPkK3PFI6PTF7PD;hQi=>
BGC823 MonKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NGDRe4k4OiCqcoO= NHzRNZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLHR|gzOyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gO{46KM7:TT6= NYfYeJNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4Nlk2OTlpPkK3PFI6PTF7PD;hQi=>
HL7702 MmXXR5l1d3SxeHnjbZR6KGG|c3H5 MkDpO|IhcHK| M{GzdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPzdyMjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOThwMkGg{txONg>? M{mzU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{O2PVk{Lz5{NUezOlk6OzxxYU6=
U-2 OS M2DLd5FJXFNic4PhfS=> NUf6XZJ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=> M1;4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NX\wUXJEeUiWUzDzd4F6 M13IO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 MYXxTHRUKHO|YYm= NFruVGFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NYPOWW9iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MY\xTHRUKHO|YYm= MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NILjRWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD NH35PYNyUFSVIIPzZZk> MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> NFjjbYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MVzxTHRUKHO|YYm= MnWxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 M2PTZZFJXFNic4PhfS=> MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M1nFTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50 NGfQRYtyUFSVIIPzZZk> Ml[wdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
fibroblast cells MXnxTHRUKHO|YYm= M{PGU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiClb370do9tKEiqIIfpcIQhfHmyZTDmbYJzd2KuYYP0JINmdGy| NGLuelk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NUjaV3pyeUiWUzDzd4F6 MkH1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 M4T5eJFJXFNic4PhfS=> NVm2endleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= NWPyeGFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 MlKydWhVWyC|c3H5 MlmxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MnTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NHvwOXpyUFSVIIPzZZk> M1:w[pFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 MoDUdWhVWyC|c3H5 NITpPZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 MYrxTHRUKHO|YYm= MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? M2fFOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; 

PubMed: 28900173     


Western blots (cropped) are shown for the indicated proteins in MDA-MB-361, BT474, and SKBR3 cells treated with AZD4547 (0, 1, 3, or 5 µM) for 72 hours. 

pFRS2; 

PubMed: 25576915     


AZD4547 inhibits FGFR2 pathway activation in SNU16 and KATOIII cells. Cells were incubated with AZD4547 at the indicated doses. Cell lysates were immunoblotted for phospho-FGFR, phospho-FRS2, phospho- and total AKT, and phospho- and total ERK.

28900173 25576915
Growth inhibition assay
Cell viability; 

PubMed: 28900173     


MDA-MB-361, BT474, and SKBR3 ErbB2-overexpressing breast cancer cells were treated with AZD4547 (0, 0.1, 0.3, 1, 3, or 5 µM) for 5 days. Then the viable fraction of each cell line was determined with an MTS assay. 

Cell viability; 

PubMed: 25576915     


FGFR2-amplified GC cells are selectively sensitive to AZD4547. In vitro CCK-8 assay across a panel of 6 GC cells demonstrated that SNU16 and KATOIII cells were extremely sensitive to AZD4547 with IC50 values of 5-10 nM. Data (n = 6) are presented as mean ± SD.

28900173 25576915
体内研究 AZD4547按3 mg/kg剂量口服处理携带KMS11肿瘤的小鼠,每天两次,与空白对照组相比,显著抑制53%肿瘤生长,AZD4547 按 12.5 mg/kg剂量每天处理一次,或按 6.25 mg/kg剂量每天处理两次,则完全抑制肿瘤,这与p-FGFR3的药效学调节剂量正相关,且降低 KMS11肿瘤细胞增殖。而且, AZD4547按 12.5 mg/kg剂量口服处理给药FGFR1融合KG1a 移植瘤模型,每天一次,抑制65% 肿瘤生长。在有效剂量水平,AZD4547不表现出抗血管生成的效果。AZD4547 对血压没有显著作用效果,因此在体内缺乏 抗-KDR 活性。相应地, AZD4547按6.25 mg/kg剂量口服处理对Cediranib敏感的移植瘤模型,包括 Calu-6, HCT-15 和 LoVo,每天两次,没有作用活性。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

AZD4547 激酶活性:

使用浓度等于或低于相对Km 的ATP,测定AZD4547抑制 FGFR1-3的人类重组激酶活性的效果。
细胞实验:[1]
- 合并
  • Cell lines: KG1a, Sum52-PE, KMS11, 和MCF7
  • Concentrations: 溶于DMSO,终浓度为 ~1 μM
  • Incubation Time: 72 小时
  • Method: 使用多种浓度AZD4547处理细胞72小时。通过 MTS 增殖实验获得抗增殖的IC50值。荧光激活细胞分选(FACS)中,细胞与70%乙醇混合,然后与碘化丙啶/RNase A标记溶液温育。使用 FACSCalibur 仪器和CellQuest分析软件测定细胞周期谱。为了分析凋亡,轻轻收集细胞和培养基,离心,然后冲洗细胞颗粒。细胞进行Annexin膜联蛋白 V-异硫氰酸荧光素(FITC)染色和碘化丙啶吸收。使用FACSCalibur仪器测定 膜联蛋白 V染色阳性细胞比例,使用CellQuest分析软件进行象限分类。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 皮下注射LoVo, HCT-15, Calu-6, KMS11 或 KG1a的雌性Swiss衍生裸鼠和SCID小鼠
  • Dosages: 1.5-50 mg/kg
  • Administration: 口服饲喂,每天一次或两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 92 mg/mL (198.45 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 463.57
化学式

C26H33N5O3

CAS号 1035270-39-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02824133 Completed Drug: AZD4547 Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Assistance Publique - Hôpitaux de Paris September 2015 Phase 1|Phase 2
NCT01824901 Completed Drug: docetaxel|Drug: AZD4547 Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group September 2013 Phase 1|Phase 2
NCT01795768 Unknown status Drug: AZD 4547 Gastric Cancer|Oesophageal Cancer|Breast Cancer|Squamous Cell Carcinoma of the Lung Royal Marsden NHS Foundation Trust|AstraZeneca September 2012 Phase 2
NCT01791985 Completed Drug: AZD4547 / anastrozole or letrozole Breast Cancer Imperial College London|Cancer Research UK|AstraZeneca July 2012 Phase 1|Phase 2
NCT01213160 Completed Drug: AZD4547 Cancer|Advanced Solid Malignancies AstraZeneca November 2010 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品

Tags: 购买AZD4547 | AZD4547供应商 | 采购AZD4547 | AZD4547价格 | AZD4547生产 | 订购AZD4547 | AZD4547代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID